Your Health, We Care
Based on the results of clinical trials, the FDA officially approved Aprocitentan (trade name Tryvio) for marketing on March 19, 2024, for the treatment of refractory hypertension patients.
This is the first drug with innovative mechanisms in the field of hypertension in over 30 years, providing a new option for the treatment of cardiovascular diseases.
